Modality
Gene Editing
MOA
PLK4i
Target
ALK
Pathway
JAK/STAT
Wet AMDT2D
Development Pipeline
Preclinical
~Mar 2021
→ ~Jun 2022
Phase 1
~Sep 2022
→ ~Dec 2023
Phase 2
Mar 2024
→ Jun 2029
Phase 2Current
NCT04850850
2,702 pts·T2D
2024-03→2029-06·Terminated
2,702 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-143.2y awayPh3 Readout· T2D
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2/3
Termina…
Catalysts
Ph3 Readout
2029-06-14 · 3.2y away
T2D
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04850850 | Phase 2/3 | T2D | Terminated | 2702 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Niralucimab | Ionis | Phase 1 | ALK | |
| 180-6098 | Innovent Bio | Phase 1 | ALK | |
| BEA-4274 | Beam | Phase 1/2 | ALK |